Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) EBIT: ¥3,400 Mil (TTM As of Mar. 2026)


SHSE:688336 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
76 GF Score
Price ¥49.75
GF Value ¥66.54
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT?

Sunshine Guojian Pharmaceutical (Shanghai) Co SHSE:688336 +20.00% 76 EBIT is ¥3,400 Mil as of Mar. 2026. GuruFocus rates SHSE:688336 with a GF Score™ of 76/100 and a GF Value™ of ¥66.54 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sunshine Guojian Pharmaceutical (Shanghai) Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥191 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3,400 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC % for the quarter that ended in Mar. 2026 was 9.57%. Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.87%.

Sunshine Guojian Pharmaceutical (Shanghai) Co  (SHSE:688336) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=765.7 * ( 1 - 9.12% )/( (7305.652 + 7230.66)/ 2 )
=695.86816/7268.156
=9.57 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8957.374 - 384.923 - ( 1266.799 - max(0, 447.022 - 6229.273+1266.799))
=7305.652

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8948.305 - 242.927 - ( 1474.718 - max(0, 277.049 - 6092.103+1474.718))
=7230.66

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunshine Guojian Pharmaceutical (Shanghai) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=765.7/( ( (1533.711 + max(4511.524, 0)) + (1534.264 + max(4337.75, 0)) )/ 2 )
=765.7/( ( 6045.235 + 5872.014 )/ 2 )
=765.7/5958.6245
=12.85 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(150.074 + 260.547 + 4547.925) - (384.923 + 0 + 62.099)
=4511.524

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(307.321 + 279.628 + 4027.85) - (242.927 + 0 + 34.122)
=4337.75

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=3400.17/43225.612
=7.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Related Terms

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Historical Data

* Premium members only.

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.31 30.27 312.04 708.83 3,319.11

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.36 76.43 227.28 2,905.04 191.43

SHSE:688336 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-EBIT falls into.


SHSE:688336
76GF Score
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Guojian Pharmaceutical (Shanghai) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,400 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥3,400 Mil mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a EBIT of ¥3,400 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current EBIT is ¥3,400 Mil. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT compare to VRTX and REGN?
Sunshine Guojian Pharmaceutical (Shanghai) Co's EBIT of ¥3,400 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co. Sunshine Guojian Pharmaceutical (Shanghai) Co's current EBIT is ¥3,400 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.54, compared to a current price of ¥49.75 — trading 25.2% below its estimated fair value. The current EBIT is ¥3,400 Mil. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current EBIT is ¥3,400 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued. The current stock price of ¥49.75 is trading 25.2% below its estimated GF Value™ of ¥66.54. GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.

Key valuation signals for SHSE:688336:

  • EBIT: ¥3,400 Mil
  • GF Value™: ¥66.54 vs. price of ¥49.75 (25.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Address No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
76GF Score

Get the complete analysis for SHSE:688336

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥49.75
Price
¥66.54
GF Value